Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPorvair Regulatory News (PRV)

Share Price Information for Porvair (PRV)

Share Price is delayed by 15 minutes
Get Live Data
790.00    -4.00 (-0.50%)
Bid:
784.00
Ask:
808.00
Spread: 24.00 (3.061%)
Market Cap: £364.16m
PRV Live PriceLast checked at - London Stock Exchange

Intraday Porvair Share Chart

Pre-close trading update

1 Dec 2014 07:00

RNS Number : 3904Y
Porvair PLC
01 December 2014
 



For immediate release 1 December 2014

 

 

 

Pre-close trading update

 

Porvair ("Porvair" or "the Group"), the specialist filtration and environmental technologies group, makes the following announcement regarding trading for the year ended 30 November 2014 ahead of its close period.

 

Porvair has continued to trade strongly throughout the year. Both divisions are expected to deliver record results, with revenue for the full year up 24% (28% at constant exchange rates) and earnings marginally ahead of current market expectations.

 

Strong operating cash flow has increased net cash at the year end to around £5m, achieved after capital investments of £5m, mostly spent on expanding manufacturing capacity to meet demand.

 

As anticipated in previous announcements, Group revenue in 2014 received a one-off boost of £20m (2013: £6m) from several large contracts, each of which is proceeding as expected. Profits on these contracts are recognised after making appropriate allowance for the outstanding liabilities, potential risks and warranties. Consequently, we expect further profits to be achieved as milestones are successfully passed over the period to 2017.

 

Revenue in the Microfiltration division was 34% (36% at constant exchange rates) ahead of the prior year. Underlying revenue growth, excluding the impact of the large projects mentioned above, was 9% (11% at constant exchange rates). Aerospace revenue continued to grow steadily and Seal Analytical recorded a record result for the year.

 

Revenue in the Metals Filtration division was 5% (11% at constant exchange rates) ahead of the prior year. Market share gains continued to be made, particularly in iron foundry filtration. The new plant in Wuhan, China, is performing as expected and revenue from aluminium filtration in China was strong.

 

The Group has adopted IAS19 Revised, Employee Benefits, in the year ended 30 November 2014. This increases the defined benefit pension scheme costs charged in the accounts and requires a revision of prior years. Earnings per share for the year ended 30 November 2013, the comparative period, are restated at 12.3 pence compared with the previously reported 12.7 pence.

 

Order books for the start of 2015 are healthy and the Group has a promising pipeline of potential projects.

 

Porvair will announce its preliminary results for the year ended 30 November 2014 on Monday 26 January 2015.

 

For further information, please contact:

 

Porvair plc

01553 765 500

Ben Stocks, Chief Executive

Chris Tyler, Group Finance Director

 

Buchanan Communications

 

0207 466 5000

Charles Ryland / Steph Watson

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration and environmental technology businesses. Its products are used in a range of niche filtration markets, and are derived from its expertise in the design and manufacture of filtration systems using ceramic, metal, plastic and carbon media. Its Seal Analytical business is a market leader in the manufacture of laboratory based water analysis equipment.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDVLFLZFFLFBK
Date   Source Headline
9th Dec 20217:00 amRNSPre-close trading update and Notice of Results
23rd Nov 202112:30 pmRNSHolding(s) in Company
5th Nov 20214:40 pmRNSSecond Price Monitoring Extn
5th Nov 20214:35 pmRNSPrice Monitoring Extension
8th Oct 20214:40 pmRNSSecond Price Monitoring Extn
8th Oct 20214:35 pmRNSPrice Monitoring Extension
27th Sep 20214:41 pmRNSSecond Price Monitoring Extn
27th Sep 20214:35 pmRNSPrice Monitoring Extension
16th Sep 20213:31 pmRNSDirector/PDMR Shareholding
14th Sep 20217:00 amRNSNine Month Trading Update
11th Aug 20214:41 pmRNSSecond Price Monitoring Extn
11th Aug 20214:35 pmRNSPrice Monitoring Extension
10th Aug 20214:40 pmRNSSecond Price Monitoring Extn
10th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20217:00 amRNSBlock listing Interim Review
5th Jul 20217:00 amRNSHalf Year Results 2021
30th Jun 20217:00 amRNSTotal Voting Rights
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:36 pmRNSPrice Monitoring Extension
23rd Jun 20214:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
10th May 20214:40 pmRNSSecond Price Monitoring Extn
10th May 20214:36 pmRNSPrice Monitoring Extension
21st Apr 20212:40 pmRNSGrant of LTSP awards
20th Apr 202112:30 pmRNSAGM resolutions and Board changes
20th Apr 20217:00 amRNSAGM Trading Update
1st Apr 20214:28 pmRNSTotal Voting Rights
17th Mar 20214:57 pmRNSHolding(s) in Company
16th Mar 20212:01 pmRNSHolding(s) in Company
2nd Mar 20214:40 pmRNSSecond Price Monitoring Extn
2nd Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20213:27 pmRNSTotal Voting Rights
26th Feb 20217:00 amRNSAcquisition of Kbiosystems Limited
22nd Feb 20213:00 pmRNSHolding(s) in Company
19th Feb 20214:35 pmRNSPrice Monitoring Extension
10th Feb 20214:36 pmRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSBlock listing Interim Review
8th Feb 20217:00 amRNSTotal Voting Rights
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
3rd Feb 20219:42 amRNSHolding(s) in Company
2nd Feb 20217:00 amRNSGrant of LTSP awards
1st Feb 20217:00 amRNSFinal Results
6th Jan 20214:41 pmRNSSecond Price Monitoring Extn
6th Jan 20214:35 pmRNSPrice Monitoring Extension
30th Dec 20203:30 pmRNSHolding(s) in Company
30th Dec 20203:30 pmRNSHolding(s) in Company
9th Dec 20203:47 pmRNSHolding(s) in Company
8th Dec 20207:00 amRNSPre-close trading update
23rd Nov 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.